ProCE Banner Activity

After Progression on Immune Checkpoint Inhibitors, What Is Next?

Clinical Thought
Immune checkpoint inhibitors (ICIs) have expanded treatment options for patients who cannot tolerate chemotherapy. Read my thoughts on using ICIs in clinical practice, as well as some of the most promising salvage strategies for patients who progress on them.

Released: June 20, 2018

Expiration: June 19, 2019

No longer available for credit.

Share

Faculty

Daniel P. Petrylak

Daniel P. Petrylak, MD

Professor of Medicine
Smilow Cancer Center
Yale University Medical Center
New Haven, Connecticut

Provided by

Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by an educational grant from

Merck Oncology

Faculty Disclosure

Primary Author

Daniel P. Petrylak, MD

Professor of Medicine
Smilow Cancer Center
Yale University Medical Center
New Haven, Connecticut

Daniel P. Petrylak, MD, has disclosed that he has received consulting fees from Bayer, Bellicum, Dendreon, Exelixis, Ferring, Johnson & Johnson, Medivation, Millennium, Pfizer, Rocher, and Sanofi; has received funds for research support from Agensys, AstraZeneca, Bayer, Dendreon, Eli Lilly, Endocyte, Genentech, Innocrin, Johnson & Johnson, MedImmune, Medivation, Merck, Millennium, Novartis, OncoGenex, Pfizer, Progenics, Roche, Sanofi, and Sotio; and has ownership interests with Bellicum and Tyme.